SCHEMBL22443761

SCHEMBL22443761

CC1(C)CC[C@H](CO[Si](C)(C)C(C)(C)C)N1C(=O)O

nearest known ligand 0.32

Predicted protein targets (top 2)

geneUniProtsupporting neighboursconfidence
▸ FKBP1A P62942 1/20 0.32
▸ DUT P33316 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22443764 1.00 FKBP1A (0.32) FKBP1ADUT
SCHEMBL22443408 0.92 FKBP1A (0.33) FKBP1ADUT
SCHEMBL22443407 0.92 FKBP1A (0.33) FKBP1ADUT
SCHEMBL22443492 0.92 FKBP1A (0.33) FKBP1ADUT
SCHEMBL24433887 0.85 SPHK1 (0.33) FKBP1ADUT
SCHEMBL28658942 0.85 SPHK1 (0.33) FKBP1ADUT
SCHEMBL28662232 0.78 ALDH1A1 (0.33) FKBP1A
SCHEMBL24433847 0.78 ALDH1A1 (0.33) FKBP1A
SCHEMBL22452856 0.78 ALDH1A1 (0.33) FKBP1A
SCHEMBL22443859 0.77 DUT (0.30) DUT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220194920-A1 HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-06-23 — — US disclosed
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2022-05-19 — — US disclosed
EP-3941468-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Atrogi AB (SE) 2022-01-26 — — EP disclosed
EP-3941913-A1 HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA Atrogi AB (SE) 2022-01-26 — — EP disclosed
WO-2020188299-A1 HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 — — WO disclosed
WO-2020188301-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA ATROGI AB (SE) 2020-09-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220152004-A1 HETEROCYCLYL(PHENYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA GPR119, SLC5A1, SLC5A2 FKBP1A 2968/4885DUT 2991/4885
US-20220194920-A1 HETEROARYL(HETEROCYCLYL)METHANOL COMPOUNDS USEFUL IN THE TREATMENT OF HYPERGLYCAEMIA SLC5A1, GPR119, SLC5A2 FKBP1A 2996/4885DUT 3160/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback